No ke aha e hiki aku ai ka heihei AI-no-Life-Science i ka Peptide Manufacturing Automation (A ma kahi e noho ai ka palena 2026)

Pane wikiwiki

The race is no longer about whether AI reaches peptide manufacturing; it is about where you draw the line. Two independent vendor-side forecasts put the peptid…

He aha ka peptide manufacturing automation e hana maoli nei i kēia manawa, hana ʻāpana ma ka hana ʻāpana

Hoʻopili pinepine ʻia ka SPPS automation, deprotection a me ka holoi ʻana, me ka ʻoki ʻana ma hope o ka hui ʻana o ke kaulahao. Loaʻa nā paepae ʻē aʻe i ka solution-phase, ligation a me nā kaʻina hana hybrid; ʻAʻole like nā peptide automation a pau i ʻehā mau ʻanuʻu.

Ka manawa pōʻaiapili no kēlā me kēia waikawa amino: AFPS kūʻē i ka synthesizer wela Ka manawa pōʻaiapili no kēlā me kēia waikawa amino: AFPS kūʻē i ka synthesizer wela: nā waiwai no AFPS automated. Ka manawa pōʻaiapili no kēlā me kēia waikawa amino: AFPS kūʻē i ka synthesizer wela. ʻikepili pae pae: AFPS automated 2.5; Mea hoʻoheheʻe ʻia 70 C 26. Puna: Hartrampf et al., ʻepekema (Nā ʻenehana Amide PDF) 2023. Ka manawa pōʻaiapili no kēlā me kēia waikawa amino: AFPS kūʻē i ka synthesizer wela AFPS automated 2.5 Pumehanamea hoʻohui 70 C 26 Puna: Hartrampf et al., ʻepekema (Nā ʻenehana Amide PDF) (2023)

ʻO ke kaomi ʻana i ka hoʻomaʻamaʻa ʻana he unahi. ʻO ke koi kālepa no nā API peptide GLP-1 hiki ke piʻi i nā ʻumi a i ʻole haneli mau kilokani i kēlā me kēia makahiki a i kekahi mau manawa e hoʻokokoke i nā pae hana metric-ton., me nā ʻanuʻu synthesis e holomua ana mai ka mg-a-g i ka ʻike ʻana ma o kg ma nā hoʻolaha lapaʻau a me multi-kg ma ka pākēneka. (Bachem, 2026). I kēlā leo, he 30-amino-acid peptide maʻamau e pono ai 30 ka hoʻohui pū ʻana a me nā pōkā deprotection, a ma 99% ʻoi aku ka maikaʻi o kēlā me kēia ʻanuʻu i mea nui ka lilo o ka hua a me ka hōʻiliʻili haumia, e hāʻawi ana i nā haneli o nā huahana pili pili (Nā Hale Hana Neuland, 2026).

No ke aha e hiki aku ai ka heihei AI-no-Life-Science i ka Peptide Manufacturing Automation (A ma kahi e noho ai ka palena 2026)

Hoʻohuihui, māwae, ʻO ka hoʻomaʻemaʻe a me ka ʻikepili hiki ke hoʻohana ʻia i nā pae like ʻole. ʻO kā lākou kūpono e pili ana i ka ʻike kaʻina hana, mea lako, ka nānā ʻana a me ka hōʻoia ʻana ma mua o ka pinepine o ka hana hou ʻana o kahi ʻanuʻu.

Hiki ke hana ʻia nā hana peptide me ka ʻole o ka nāwaliwali ʻana i ka maikaʻi a i ʻole ke kuleana kuleana

ʻO nā ʻanuʻu i hiki ke hoʻomaʻamaʻa ʻia ʻo ia nā mea e hana ai ka mea hana i nā hōʻike a hōʻoia ʻia nā hōʻike i kahi kūlana ʻenehana-neutral.. Loaʻa maʻalahi ka synthesis holo wikiwiki 2.5 mau minuke no ka ʻakika amino 26 minuke no kēlā me kēia amino acid no nā mea kūʻai aku mehana wela ma 70 degere C, me nā koena i hoʻohui ʻia i ka liʻiliʻi 40 kekona a hiki i 90 degere C (Hartrampf et al., ʻepekema, 2020). Hoomaemae kaulike o 96 lawe nā peptides 1.55 hora a me 1 lita o ka solvent versus 56 hora a me 50 nā lita no ke kaʻina RP-HPLC, he 36-fold ka manawa a me 50-fold ka ho'ēmi solvent (Palapala biotage, palapala kuai V.6).

ʻO ka mea e pale ai i kēia mau ʻanuʻu, ʻaʻole e loli ke ala hōʻoia no ka mea e hana ana kahi mīkini. I Q2(R2) koi ʻia ke kaʻina hana analytical no kāna kumu i manaʻo ʻia a e ʻāpono ʻia ka pūʻolo hōʻoia e ka huahana, matrix, analyte a me ka ʻenehana; ʻo ia ka ʻenehana-neutral a no laila pili i nā ʻano hana peptide QC kōkua AI a i ʻole (I Q2(R2), mana hope, Nowemapa 2023). Hoʻonui ka hoʻomohala hoʻomohala ʻana o ICH Q14 i ka loiloi pilikia o nā ʻāpana kaʻina hana analytical, uni- a i ʻole nā ​​hoʻokolohua multivariate a i ʻole hoʻohālike, a me kahi hoʻolālā hoʻomalu i wehewehe ʻia me nā kiko hoʻonohonoho a me nā pae e komo pū ana me nā ʻāpana hoʻolālā e hiki ke hoʻohana ʻia (I Q14, mana hope, Nowemapa 2023).

ʻO ke alakaʻi hōʻoia ʻana o ka polokalamu kamepiula a FDA no ka hana ʻana a me ka lako polokalamu ʻōnaehana maikaʻi he ʻano lāʻau lapaʻau. He mea ʻike paha kāna mau manaʻo pili i ka pilikia, akā, ʻaʻole ia e hoʻokumu maʻalahi i nā koi no ka lako polokalamu hana peptide pharmaceutical.

Ki Takeaway: ʻO ka hoʻomaʻamaʻa ʻana i kahi ʻanuʻu a me ka hoʻololi ʻana i ka hoʻoholo e pili ana i kēlā ʻanuʻu he mau papahana like ʻole me nā kaumaha hōʻike like ʻole.

ʻO nā ʻanuʻu e pono e noho ma lalo o ka mana kanaka, a no ke aha

Hoʻomohala ʻana i ka lāʻau peptide Hoʻohui hou i ka Peptide Synthesis ʻO ke alakaʻi synthetic-peptide o ka EMA e hoʻoholo i ka hoʻoholo hoʻokuʻu ʻana i ka hana a ke kanaka. ʻO ka maʻemaʻe kekahi o nā ʻano koʻikoʻi koʻikoʻi koʻikoʻi no nā peptides synthetic; koi ʻia ka hōʻoia ʻana o ka hale; Pono e hoʻomalu ʻia ka ʻike counterion a me ka ʻike me ka palena o luna; a ʻaʻole ʻae ʻia kahi ʻāpana kikoʻī i kapa ʻia ʻo "nā haumia kaumaha molekala kiʻekiʻe"., no ka mea, dimer, trimers, ʻO nā oligomers a me nā mea hōʻuluʻulu pono e wehewehe ponoʻia (EMA, i ka ikaika 1 Iune 2026).

ʻO ke kūlana o ka FDA ma AI he kikoʻī. ʻO Ianuali 2025 ʻO ke alakaʻi ʻana ma AI e kākoʻo i ka hoʻoholo hoʻoholo ʻana ua kapa ʻia "ʻAʻole no ka hoʻokō. Loaʻa nā manaʻo paʻa ʻole” (FDA, 2025), a ke hāpai nei ia i kahi papa hana loiloi hilinaʻi e pili ana i ka pilikia kahi i hoʻokumu ʻia ai ka hilinaʻi ma o nā hōʻike hilinaʻi no kahi pōʻaiapili o ka hoʻohana. (Kakau Federal, palapala FDA-2024-D-4689, 2025).

ʻO ke kemika ponoʻī ke wehewehe i ke kumu e kūʻē ai kekahi mau hoʻoholo i ka ʻelele. Hoʻokumu ʻia ka Aspartimide i ka wā o ka deprotection Fmoc maʻamau me 20% piperidine ma DMF, a ʻo nā kumu waiwai pKa ma hope o kēlā ʻanuʻu he piperidine 11.1, HOBt 4.6 a me ka ʻakika conjugate DBU 13.5 (King et al., 2025). ʻO ke koho ʻana i kahi kumu ke koho ʻana i kahi ʻaoʻao ʻaoʻao, ʻo ia ka hoʻoholo ʻana o ke kemika kūpono, ʻaʻole he polokalamu paʻamau.

Ma kahi o ka peptide manufacturing automation i kēia manawa i hāʻule: nā kaʻina paʻakikī a me ka milligram-to-kilogram scale-up

he peptide synthesis workflow diagram e hōʻailona ana i kēlā me kēia ʻāpana hana - hoʻohui, deprotection, holoi, māwae, ka hoomaemae ana

96-hoʻomaʻemaʻe peptide: parallel vs sequential hoʻomaʻemaʻe peptide: parallel vs sequential, e like me ka manao mai ke kumu i oleloia. 96-hoʻomaʻemaʻe peptide: parallel vs sequential. ʻikepili pā hui: Kaulike 96-punawai: Manawa (hola) 1.55, Mea hoʻoheheʻe (lita) 1; RP-HPLC kaʻina: Manawa (hola) 56, Mea hoʻoheheʻe (lita) 50.Puna: Biotage peptide synthesis brochure (palapala kūʻai, V.6) . 96-hoʻomaʻemaʻe peptide: parallel vs sequential 0 25 50 75 100 Manawa (hola) Mea hoʻoheheʻe (lita) 1.55 1 Kaulike96-pono 56 50 KakaulikeRP-HPLC Puna: Biotage peptide synthesis brochure (palapala kūʻai, V.6)

Nā kaʻina paʻakikī ma luna 50 i 60 He paʻakikī nā amino acids me nā protocol SPPS automated, a ʻaʻohe protocol kūikawā no nā peptides hydrophobic kiʻekiʻe: ʻO kēlā me kēia synthesis hou e pono ai ka hoʻonui kūikawā (Mueller et al.., 2020). ʻO ka mīkini ka hoʻohui i ka resin. Ua wehewehe ʻia nā kaʻina paʻakikī e like me nā peptides i hoʻopau maikaʻi ʻia i ka wā i hoʻopili ʻia i ke kākoʻo paʻa, ka pale ʻana i ka deprotection piha a me nā ʻanuʻu hoʻohui, a he nui na koena hydrophobic e like me Leu, ʻO Val, ʻO Phe lāua ʻo Ile; ʻO Val a me Ile nā ​​lālā beta, me ka glycine inducing beta-sheet packing i hui pū me kēia (Mueller et al., 2020).

Hiki ke maʻalahi nā kumu Asp-X i ka hoʻokumu ʻana i ka aspartimide ma muli o ke kaʻina a me nā kūlana deprotection.. E koho a hōʻoia i kahi ala kūpono, inā paha i hoʻokō ʻia me ka lima a i ʻole ka ʻakomi. ʻO ke koena aʻe i loko o kahi kumu ʻaʻole pono ke koena C-terminal o ka peptide holoʻokoʻa.

ʻIke ʻia ke kaupaku hiki i ka ʻikepili hana i paʻi ʻia. ʻO nā hua i hoʻokaʻawale ʻia ma waena o nā kaʻina protein holo wikiwiki 2.2 i 19.0 mg, a i ʻole 1 i 5%, ma hope o ka hoʻomaʻemaʻe HPLC, me ka proinsulin (86 aa) ma 2.2 mg a me ka HIV-1 protease (99 aa) ma 5.3 mg, a o ke kaulahao loa ma 164 aa pau 327 nā ʻano hopena (Hartrampf et al., ʻepekema, 2020). He hopena noiʻi kēlā, ʻaʻole he koi hana.

ʻO ka Scale-up kahi aʻo ʻokoʻa. ʻO ka nānā ʻana i ka Milligram e ana i ka hiki ke hana, ʻaʻole hana ikaika: ma ka pālākiō kilo pono e hoʻolālā hou ʻia ke kaʻina hana a puni ka geometry reactor, ka hui ʻana a me ka hoʻoili nui ʻana, wehe wela, hana resin, hoʻomaʻemaʻe hoʻouka a me ka haumia-profile hoʻololi, No laila, ʻo ka hoʻoili ʻana ke kaʻina hana hou ʻana me nā pūʻulu pailaka ma mua o ka hoʻopili ʻana i ka protocol (Nā Hana Hana Biotech Global, 2026). ʻO ka hiki ke ala: SPSS, LPPS, ʻAʻole hiki ke hoʻololi ʻia nā hale hoʻolālā hybrid convergent a me recombinant-plus-synthetic, a ʻo ka hoʻomaʻemaʻe ʻana ma mua o ka synthesis e hoʻonohonoho pinepine i ka leo hoʻouna, no laila hiki i kahi pūnaewele ke kūkulu i kahi mole a hiki ʻole ke hoʻomaʻemaʻe iā ia i ka nui i makemake ʻia (CDMO Hub, 2026).

He aha nā moʻolelo e pono ai ke kuhikuhi ʻana no ka mea loiloi e pale aku i kahi hoʻoholo pūʻulu ʻakomi

he puʻupuʻu puʻupuʻu uila hoʻomāʻewaʻewa me nā kahua kuhikuhi-kea i hōʻike ʻia - helu nui, ʻano ID, kolamu

Hiki ke pale ʻia ka hoʻoholo pūʻulu ʻokoʻa i ka wā e ʻae ai ka pūʻolo moʻolelo i kahi loiloi e kūkulu hou i ka mea a ka ʻōnaehana i hana ai a nāna i ʻae iā ia.. 21 CFR 11.10(a) pono ka hōʻoia o nā ʻōnaehana e hōʻoia i ka pololei, hilinaʻi, ka hana i manaʻo ʻia a me ka hiki ke ʻike i nā moʻolelo kūpono ʻole a i hoʻololi ʻia, a 11.10(e) ʻO Peptide P pono palekana, hana kamepiula, ʻO nā ala hoʻokele i hoʻopaʻa ʻia i ka manawa ʻaʻole i hūnā i ka ʻike i hoʻopaʻa ʻia ma mua a mālama ʻia ma ka liʻiliʻi loa e like me nā moʻolelo kumuhana. (21 Mahele CFR 11, i kēia manawa e like me ka ikaika).

Pono ka papa inoa e kuhikuhi i ka hoʻoholo. Pono e hōʻike ʻia nā moʻolelo uila i paʻi ʻia i ka inoa paʻi o ka mea hoʻopaʻa inoa, ka lā a me ka manawa o ka pūlima, a me ka manaʻo e pili ana i ka pūlima, e like me ka loiloi, ʻae ʻia, kuleana a mea kākau paha (21 CFR 11.50(a), i kēia manawa e like me ka ikaika). ʻO ka MHRA Hoʻohui ʻia ʻo Peptide maʻamau Hoʻohui nā loina ALCOA e pili ana ka ʻikepili, hiki ke heluhelu, hoʻokahi manawa, kumu a pololei, me ka "+" hoʻohui piha, kūlike, hoʻomanawanui a loaʻa, a ʻaʻohe ʻokoʻa o nā manaʻo i kēlā me kēia acronym i hoʻohana ʻia (MHRA, 2018).

Hoʻonohonoho pū ka MHRA i ka manaʻolana mana: manaʻo ʻia nā hui e hoʻokō, hoʻolālā a hana i kahi ʻōnaehana palapala e hāʻawi ana i kahi kūlana ʻae ʻia o ka mana e pili ana i ka pilikia pono o ka ʻikepili me ke kumu kākoʻo., e like me ka hoʻopaʻa ʻana i ka ʻikepili pili pono (MHRA, 2018). ʻAʻole manaʻo ʻia ka nānā ʻana i ka forensic maʻamau; nā loiloi manawa (MHRA, 2018).

ʻO ka peptide-specific layer mai ka EMA. I ka wā SPPS, nā ʻanuʻu maʻamau e like me ka deprotection, holoi, ʻAʻole pono e wehewehe kikoʻī ʻia ka hui ʻana a me ka capping i kēlā me kēia manawa i hāʻawi ʻia nā kūlana a maopopo kahi i hoʻohana ʻia ai; pono e wehewehe kikoʻī ʻia ka pae hope a me ka deprotection me nā scavengers; a ua manaʻo ʻia ka hiki ʻana o nā mea mai nā ʻanuʻu synthesis ma o ka mea hana hope loa (EMA, pono 1 Iune 2026).

ʻO ka mea i ana i nā loaʻa a me nā pilikia o ka peptide manufacturing automation e hāʻawi maoli

Hōʻike nā hōʻikeʻike hoʻomaʻemaʻe a me ka synthesis wikiwiki i paʻi ʻia ma lalo o kā lākou kūlana i ʻōlelo ʻia. Nā manawa pōʻaiapili hoʻolaha, ʻAʻole pono ka hoʻohālikelike ʻana i nā mea hoʻoheheʻe a me nā unahi. E hoʻopaʻa i nā pae hoʻohālike like, me ka hoomaemae a me ka hoola ana.

Hoʻohana mea hoʻoheheʻe: LPPS vs SPPS maʻamau Hoʻohana mea hoʻoheheʻe: LPPS vs SPPS maʻamau: waiwai no LPPS (Ajiphase), SPPS maʻamau. Hoʻohana mea hoʻoheheʻe: LPPS vs SPPS maʻamau. ʻikepili lollipop: LPPS (Ajiphase) 174; SPPS maʻamau 2183. Puna: Hoʻomaʻamaʻa i ka synthesis o ka peptide therapeutics (Kemika ʻōmaʻomaʻo / PMC) 2022. Hoʻohana mea hoʻoheheʻe: LPPS vs SPPS maʻamau LPPS (Ajiphase) 174 SPPS maʻamau 2183 Puna: Hoʻomaʻamaʻa i ka synthesis o ka peptide therapeutics (Kemika ʻōmaʻomaʻo / PMC) (2022)

Lawe ʻia ka koho solvent i kahi hōʻailona kumukūʻai hiki ke ana. ʻO ke kumukūʻai hoʻoheheʻe no kēlā me kēia amino-acid coupling cycle holo mai 151 EUR no DMSO/EtOAc (1:9) me ka hana hou ana, i 297 EUR no DMF, 406 EUR no NBP/EtOAc (1:1), a 431 EUR no DMSO/EtOAc me ka hana hou ole (Hōʻike manaʻo kemika ʻōmaʻomaʻo, 2022). ʻO Dna A me Peptide Synthesis

Hiki i nā Epimers ke loaʻa ka nui like; ʻokoʻa nā huahana holoi i ka nui o ke koena i nalowale. Hiki i nā mea ʻelua ke hoʻohālikelike i ka koho chromatographic, akā, ʻaʻole lāua ʻelua kokoke i ka isobaric i ka peptide paʻa. E hoʻohana i ka diagnostic mass a me ka hōʻike hoʻokaʻawale kūpono i ka haumia.

ʻO nā mea i hāʻawi ʻole ʻia e nā kumu waiwai like ia. ʻAʻohe kumu i kiʻi ʻia e hoʻohālikelike i kahi hana peptide i hāʻule-batch a i ʻole ka helu o waho o ka kikoʻī., a ʻaʻohe mea e helu ana i ka manawa huli hoʻokuʻu hoʻāʻo ʻana a i ʻole ka hōʻemi ʻana mai ka QC automated.. Pono e mālama ʻia ka hoʻemi defect-rate ma ke ʻano he qualitative a hoʻoili ʻia i ka ʻikepili i loko o ke kaʻina hana ma mua o ke koi ʻia ʻana e kūʻē i kahi baseline i ana ʻole ʻia..

Pehea e pono ai ka peptide R&Hoʻonohonoho ka hui D i kāna hoʻolaha automation ponoʻī?

he lua-axis grid e hoʻolālā ana i nā hana peptide ma o ka hoʻohuli ʻana i ka ʻanuʻu e kūʻē i ka hopena hoʻoponopono, me ka

E hoʻopaʻa i ka hoʻopuka ʻana i ka automation me ka hoʻohana ʻana i ka pilikia maoli, hiki ke ʻike, hoʻolālā hoʻomalu a me nā pono hōʻoia. I Q9(R1), hoʻopau ʻia i Ianuali 2023, hāʻawi i kahi papa hana hoʻokele pilikia, ʻaʻole he kauoha koi o nā papahana automation. Pono e loiloi ʻia nā mana lako polokalamu lāʻau lapaʻau ma lalo o ke kahua kūpono. Nā peptide

Pono e hoʻokaʻawale ʻia nā hihia palena ʻelua mai ka automation mua. Nā kaʻina paʻakikī ma luna 50 i 60 Pono nā ʻakika amino i ka hoʻoponopono kikoʻī (Mueller et al.., 2020), a ʻo ka milligram-to-kilogram ka hoʻoili ʻana ʻo ia ke kaʻina hana hou ʻana ma mua o ka hoʻopili ʻana i ka protocol (Nā Hana Hana Biotech Global, 2026). ʻO ka hoʻomaʻamaʻa ʻana ma mua o ka hoʻomaopopo ʻana i ke kaʻina hana hoʻomaʻemaʻe wale i ka hemahema.

Nīnau pinepine

Ke paʻa mau nei ka hihia automation maʻamau no ka leo kiʻekiʻe, nā kaʻina hana maikaʻi?

ʻAe, a ma laila ka hihia i ikaika loa ai. Pōkole, ʻO nā kaʻina i hoʻopau maikaʻi ʻia e holo ana i ka pōʻai like i nā haneli he mau manawa kūpono e uku ai ka mana maikaʻi o ka peptide synthesis automated nona iho., no ka mea hiki ke hana hou ʻia nā ʻanuʻu hoʻohui a me ka deprotection a paʻa nā hopena analytical. Hoʻomaka wale ka neʻe ʻana o ka palena ke hoʻopau maikaʻi ʻia kahi kaʻina ma ka resin, no ka mea, ʻaʻole hiki ke hoʻoponopono ʻia ka hui ʻana a me ka deprotection me ka hoʻonohonoho paʻa. ʻAʻole hewa ka hihia maʻamau; ʻoi aku ka haiki ma mua o ke ʻano o ka ʻōlelo maʻamau.

Ua holo mua mākou i kahi laina automated. Hiki ke hoʻihoʻi ʻia ka palena kanaka?

Hiki ke hoʻoponopono hou a me nā wahi hoʻomalu, akā e loiloi i ka polokalamu, mea kani, hōʻoia, ka pono o ka ʻikepili a me ke kumukūʻai hana ma mua o ke koho ʻana i kahi hoʻololi. ʻAʻole pono e hopu ʻia nā mea hōʻike e pono ai nā lako e kū nei.

Pehea mākou e pane ai i ka mea kūʻai aku i nā helu ROI no AI i ka hana peptide?

E mālama iā lākou i hōʻoia ʻole ʻia a ʻike ʻoe i ke ʻano. I kēia manawa, ʻaʻohe mea i hoʻonohonoho ʻia no ka hoʻomaʻemaʻe ʻana o AI-optimised ma waena o nā kaʻina paʻakikī, no laila, kau ʻia kekahi helu hoʻihoʻi poʻomanaʻo ma luna o ka hui pū ʻana o ka mea kūʻai aku, unahi a me nā helu hope, a ʻaʻole e hoʻoili iā ʻoe. E noi i ka hoʻonohonoho hoʻohālike, ka mahele paʻakikī o ke kaʻina, ka unahi, a me ka pukaaniani manawa, a inā ʻaʻole loaʻa ia mau mea, holo i ka hoʻohālikelike ma kāu mau kaʻina paʻakikī ma mua o ka hana ʻana.

Ke hana nei ka EMA 1 Iune 2026 Hoʻololi ka lā kūpono i ka mea a mākou e kākau ai no nā pae SPPS maʻamau?

Hoʻololi ia i ka manaʻolana traceability ma mua o ke kemika. Ua lilo ke alakaʻi synthetic-peptide o EMA i mea maikaʻi ma 1 Iune 2026, a no nā ʻanuʻu paʻa paʻa maʻamau e manaʻo ʻia e hōʻike ka palapala i ke ʻano o ka mālama ʻia ʻana o kēlā me kēia ʻanuʻu a pehea e hoʻopili ai ka moʻolelo i ka synthesis a hiki i ka mea hana hope.. Inā ua hana mua kāu mau ʻanuʻu automated i ka wā, nā moʻolelo pili, ʻO ka hana nui ka palapala ʻāina iā lākou i kēlā manaʻo; ina aole lakou, ʻO kēlā āpau ka mea nui ma lalo o nā koi i kēia manawa.

No ke aha e hiki ʻole ai ke hāʻawi wale ʻia kahi kaʻina paʻakikī i kahi synthesizer automated?

Hiki i nā kaʻina paʻakikī ke koi i nā loli i ka solvent, hoʻopili ʻana, deprotection, mahana wela, resin a i ʻole ala hui. ʻAʻole hōʻoia ka lōʻihi i ka hoʻonā maikaʻi ʻole, a hiki i ka hoʻomohala ʻana i nā kaʻina hana automate kūpono ke hoʻomaikaʻi i ka hana. E hōʻoia i ke ʻano hoʻokolohua ma ka pālākiō i manaʻo ʻia.

Ka hopena

Kākoʻo nā mea hōʻike i kēia māhele like ʻole, a ʻo ia ke kūlana ʻoiaʻiʻo. Ana ʻia a nui ka loaʻa ʻana o ka wā pōʻaiapili a me ka solvent. ʻAʻole helu ʻia ka hoʻomaikaʻi ʻana i ka helu kīnā a me ka hoʻokuʻu ʻana i nā kumu i kiʻi ʻia, no laila ʻaʻole pono e koi ʻia. Nā kaʻina paʻakikī ma luna 50 i 60 mau ʻakika amino a me ka milligram-to-kilogram transfer i ke kūkulu ʻana i alakaʻi ʻia e ke kanaka (Mueller et al.., 2020; Nā Hana Hana Biotech Global, 2026).

ʻO ka ʻanuʻu aʻe he loiloi moʻolelo, ʻaʻole he kauoha kūʻai. Ma mua o ka pūʻulu automated mua, hōʻoia i ka hōʻoia ʻana o ka ʻōnaehana, ala hoʻokolo, Hiki ke hana ʻia ka hōʻike pūlima a me ke kaulahao traceability ma ke koi, no ka mea, ʻo ia nā mea waiwai a ka mea loiloi e noi mua ai (21 Mahele CFR 11, i kēia manawa e like me ka ikaika; MHRA, 2018).


Mea hoʻopuka: MOL Changes. Hoʻohou 15 ʻOkakopa 2026. Hoʻopili kēia ʻatikala i nā kumu lehulehu i ʻōlelo ʻia a hāʻawi i kahi hoʻolālā hoʻolālā. ʻAʻole ia e hōʻike i kahi loiloi hoʻolako kūʻokoʻa a i ʻole kahi noiʻi hoʻokolohua MOL Changes kumu.

Hōʻike kālepa: Hāʻawi ʻo MOL Changes i nā lawelawe peptide a loaʻa iā ia kahi hoihoi pāʻoihana i kēia kumuhana. Pono e hoʻopaʻa ʻia ka mana o ka papahana a me ka laulā analytical e kūʻē i ka hoʻohana i manaʻo ʻia a me kahi kikoʻī i kākau ʻia.

Jinling Liu

Jinling Liu

Kaʻina hana R&D a me ka Mea Hana Hana Kaʻike kumu: Hoʻonui kaʻina hana, kemika ʻōmaʻomaʻo, hoʻomaikaʻi maikaʻi, Hoʻokō ka hana GMP.

Pilikino: He loea ʻo Jinling Liu i ka unuhi ʻana o nā lāʻau peptide mai ka pālākiō keʻena (pae milligram) i ka hana pāʻoihana (pae kilokani). Ua kūpaʻa ʻo ia i ka hōʻemi nui ʻana i nā kumukūʻai hana peptide a me ka hōʻemi ʻana i ka pollution kaiapuni ma o ka hoʻonui ʻana i nā kūlana cleavage., ka hoʻomaikaʻi ʻana i nā lakio o nā condensation reagents, a me ka hoʻolauna ʻana i ka ʻenehana synthesis kahe mau. Ua alakaʻi ʻo ia i ka optimization o nā papahana peptide he nui, ka loaʻa ʻana o ke kumu kūʻai haʻahaʻa, hoʻomaʻemaʻe kiʻekiʻe ma ka pālākiō 100-kilogram.

ʻIke ʻia & Nā alakaʻi hoʻoponopono
Nānā ʻia e: Ka poe akamai kumuhana
Kaʻana like i kēia ʻatikala
Home Huli Whatsapp Nā lawelawe Huahana